One-step chemiluminescent immunoassay of free thyroxin with acridinium-ester-labeled thyroxin evaluated and compared with a two-step radioimmunoassay.

1988 ◽  
Vol 34 (12) ◽  
pp. 2556-2560 ◽  
Author(s):  
J Y Bounaud ◽  
M P Bounaud ◽  
F Begon
Keyword(s):  
Confidence Interval ◽  
Significant Interaction ◽  
Binding Proteins ◽  
Clinical Status ◽  
One Step ◽  
Chemiluminescent Immunoassay ◽  
Therapy Treatment ◽  
Acridinium Ester

Abstract This new one-step chemiluminescent immunoassay of free thyroxin (FT4) involving a thyroxin-immunoglobulin conjugate labeled with acridinium ester (Magic Lite System; Ciba Corning Diagnostics Corp., Medfield, MA) is rapid (one 1-h incubation), requires two calibrators per run, and takes 10 s per sample for the quantification step. Analytical performances were excellent: within- and between-run CVs of less than 10% in the working range, no significant effect of hemolysis, bilirubin, or lipemia, and no significant interaction between the conjugate and the thyroxin-binding proteins. Magic Lite results (y) correlated well with those obtained by the Sclavo (x) two-step radioimmunoassay (Sclavo, Siena, Italy): y = 1.35x + 1.32 (r = 0.94, n = 267, P less than 0.001, Sxy = 6.29). Clinical sensitivities (diagnostic efficiencies) for hypothyroidism and hyperthyroidism were 0.91 and 0.98 for normal interval limits of 12 and 21.5 pmol/L (95% confidence interval). Magic Lite results in situations where patient therapy, treatment, or unusual conditions can result in a lack of correlation between the clinical status and the FT4 values were qualitatively the same as those obtained by the Sclavo assay.

Effects of dopamine and domperidone on ventilatory sensitivity to hypoxia after 8 h of isocapnic hypoxia

1999 ◽  
Vol 86 (1) ◽  
pp. 222-229 ◽  
Author(s):  
Michala E. F. Pedersen ◽  
Keith L. Dorrington ◽  
Peter A. Robbins
Keyword(s):  
Confidence Interval ◽  
Lower Limit ◽  
Analysis Of Variance ◽  
Significant Interaction ◽  
Low Dose ◽  
Ventilatory Response ◽  
Hypoxic Ventilatory Response ◽  
Dopaminergic Activity ◽  
Sustained Hypoxia

Acclimatization to altitude involves an increase in the acute hypoxic ventilatory response (AHVR). Because low-dose dopamine decreases AHVR and domperidone increases AHVR, the increase in AHVR at altitude may be generated by a decrease in peripheral dopaminergic activity. The AHVR of nine subjects was determined with and without a prior period of 8 h of isocapnic hypoxia under each of three pharmacological conditions: 1) control, with no drug administered; 2) dopamine (3 μg ⋅ min−1 ⋅ kg−1); and 3) domperidone (Motilin, 40 mg). AHVR increased after hypoxia ( P ≤ 0.001). Dopamine decreased ( P ≤ 0.01), and domperidone increased ( P ≤ 0.005) AHVR. The effect of both drugs on AHVR appeared larger after hypoxia, an observation supported by a significant interaction between prior hypoxia and drug in the analysis of variance ( P ≤ 0.05). Although the increased effect of domperidone after hypoxia of 0.40 l ⋅ min−1 ⋅ %saturation−1[95% confidence interval (CI) −0.11 to 0.92 l ⋅ min−1 ⋅ %−1] did not reach significance, the lower limit for this confidence interval suggests that little of the increase in AHVR after sustained hypoxia was brought about by a decrease in peripheral dopaminergic inhibition.

One-step fabrication of LSPR-tuneable reconfigurable assemblies of gold nanoparticles decorated with biotin-binding proteins

Nanoscale ◽  
2017 ◽  
Vol 9 (47) ◽  
pp. 18855-18860 ◽  
Author(s):  
R. de la Rica
Keyword(s):  
Gold Nanoparticles ◽  
Binding Proteins ◽  
Chemical Cues ◽  
Biotin Binding ◽  
One Step

Biotin-binding proteins trigger the assembly of chain-like clusters of gold nanoparticles that reconfigure as a function of chemical cues in their environment.

scholarly journals Randomized, Placebo-Controlled, Double-Blind Pilot Study of D-Cycloserine in Chronic Stroke

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
Andrew J. Butler ◽  
Justiss Kallos ◽  
Stephen N. Housley ◽  
Michelle C. LaPlaca ◽  
Stephen F. Traynelis ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Stroke Survivors ◽  
Double Blind ◽  
Quality Of Life Measures ◽  
Nmda Receptor Function ◽  
The Usa ◽  
Physical Therapy Treatment ◽  
Preliminary Study ◽  
Therapy Treatment

Stroke is a leading cause of death and disability in the USA. Up to 60% of patients do not fully recover despite intensive physical therapy treatment. N-Methyl-D-aspartate receptors (NMDA-R) have been shown to play a role in synaptic plasticity when activated. D-Cycloserine promotes NMDA receptor function by binding to receptors with unoccupied glycine sites. These receptors are involved in learning and memory. We hypothesized that D-cycloserine, when combined with robotic-assisted physiotherapy (RAP), would result in greater gains compared with placebo + RAP in stroke survivors. Participants (n=14) were randomized to D-cycloserine plus RAP or placebo plus RAP. Functional, cognitive, and quality-of-life measures were used to assess recovery. There was significant improvement in grip strength of the affected hand within both groups from baseline to 3 weeks (95% confidence interval for mean change, 3.95 ± 2.96 to 4.90 ± 3.56 N for D-cycloserine and 5.72 ± 3.98 to 8.44 ± 4.90 N for control). SIS mood domain showed improvement for both groups (95% confidence interval for mean change, 72.6 ± 16.3 to 82.9 ± 10.9 for D-cycloserine and 82.9 ± 13.5 to 90.3 ± 9.9 for control). This preliminary study does not provide evidence that D-cycloserine can provide greater gains in learning compared with placebo for stroke survivors.

scholarly journals Highlights on Novel Technologies for the Detection of Antibodies to Ro60, Ro52, and SS-B

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
M. Infantino ◽  
C. Bentow ◽  
A. Seaman ◽  
M. Benucci ◽  
F. Atzeni ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Autoimmune Diseases ◽  
Qualitative Agreement ◽  
San Diego ◽  
Good Qualitative Agreement ◽  
Dot Blot ◽  
Systemic Autoimmune Diseases ◽  
Novel Technologies ◽  
Chemiluminescent Immunoassay ◽  
Inova Diagnostics

Objective. We aimed to compare a chemiluminescent immunoassay (CIA, QUANTA Flash) on BIO-FLASH with a multiplex flow immunoassay (MFI) on BioPlex 2200 for the detection of antibodies to Ro60, Ro52, and SS-B.Methods. The study included 241 samples, from patients suffering from systemic autoimmune diseases (n=108) as well as disease controls (n=133). All samples were tested for anti-Ro52, anti-Ro60, and anti-SS-B (La) antibodies on QUANTA Flash (INOVA Diagnostics, San Diego, USA) and BioPlex 2200 (Bio-Rad Laboratories Inc., Hercules, USA). Discrepant samples were tested by two independent methods: BlueDot/ANA and QUANTRIX Microarray (both D-tek, Belgium).Results. The overall qualitative agreements were 95.4% (95% confidence interval, CI 92.0–97.7%) for anti-Ro52, 98.8% (95% CI 96.4–99.7%) for anti-Ro60, and 91.7% (95% CI 87.5–94.9%) for anti-SS-B antibodies. There were 34 discrepant samples among all assays (20 anti-SS-B, 11 anti-Ro52, 3 anti-Ro60). 30/33 of retested samples (by D-tek dot blot) agreed with the QUANTA Flash results. Similar findings were obtained with QUANTRIX Microarray kit.Conclusion. QUANTA Flash and BioPlex 2200 show good qualitative agreement. The clinical performances were similar for anti-Ro52 and anti-Ro60 autoantibodies while differences were observed for anti-SS-B (La) antibodies.

Competitive Chemiluminescent Immunoassay for Estradiol Using anN-Functionalized Acridinium Ester

1996 ◽  
Vol 11 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Hiroshi Sato ◽  
Hiroshi Mochizuki ◽  
Yuki Tomita ◽  
Toshio Izako ◽  
Naofumi Sato ◽  
...  
Keyword(s):  
Chemiluminescent Immunoassay ◽  
Acridinium Ester

Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by RNA-binding specificities

1988 ◽  
Vol 8 (5) ◽  
pp. 2237-2241 ◽  
Author(s):  
M S Swanson ◽  
G Dreyfuss
Keyword(s):  
Binding Proteins ◽  
Rna Binding ◽  
Binding Affinities ◽  
High Binding ◽  
Heterogeneous Nuclear Ribonucleoprotein ◽  
Hnrnp Proteins ◽  
Hnrnp C ◽  
One Step ◽  
Nuclear Ribonucleoprotein ◽  
Very High

Several proteins of heterogeneous nuclear ribonucleoprotein (hnRNP) particles display very high binding affinities for different ribonucleotide homopolymers. The specificity of some of these proteins at high salt concentrations and in the presence of heparin allows for their rapid one-step purification from HeLa nucleoplasm. We show that the hnRNP C proteins are poly(U)-binding proteins and compare their specificity to that of the previously described cytoplasmic poly(A)-binding protein. These findings provide a useful tool for the classification and purification of hnRNP proteins from various tissues and organisms and indicate that different hnRNP proteins have different RNA-binding specificities.

scholarly journals Development, Implementation, and Evaluation of an In-Hospital Optimized Early Warning Score for Patient Deterioration

2020 ◽  
Vol 5 (1) ◽  
pp. 238146831989966 ◽  
Author(s):  
Cara O’Brien ◽  
Benjamin A. Goldstein ◽  
Yueqi Shen ◽  
Matthew Phelan ◽  
Curtis Lambert ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Early Warning ◽  
Clinical Decision Making ◽  
Risk Model ◽  
Clinical Status ◽  
Area Under The Curve ◽  
Clinical Decision ◽  
Early Warning Score ◽  
Support Tool ◽  
National Early Warning Score

Background. Identification of patients at risk of deteriorating during their hospitalization is an important concern. However, many off-shelf scores have poor in-center performance. In this article, we report our experience developing, implementing, and evaluating an in-hospital score for deterioration. Methods. We abstracted 3 years of data (2014–2016) and identified patients on medical wards that died or were transferred to the intensive care unit. We developed a time-varying risk model and then implemented the model over a 10-week period to assess prospective predictive performance. We compared performance to our currently used tool, National Early Warning Score. In order to aid clinical decision making, we transformed the quantitative score into a three-level clinical decision support tool. Results. The developed risk score had an average area under the curve of 0.814 (95% confidence interval = 0.79–0.83) versus 0.740 (95% confidence interval = 0.72–0.76) for the National Early Warning Score. We found the proposed score was able to respond to acute clinical changes in patients’ clinical status. Upon implementing the score, we were able to achieve the desired positive predictive value but needed to retune the thresholds to get the desired sensitivity. Discussion. This work illustrates the potential for academic medical centers to build, refine, and implement risk models that are targeted to their patient population and work flow.

scholarly journals Determinants of the repetitive-CMAP occurrence and therapy efficacy in slow-channel myasthenia

Neurology ◽  
2020 ◽  
Vol 95 (20) ◽  
pp. e2781-e2793
Author(s):  
Li Di ◽  
Hai Chen ◽  
Yan Lu ◽  
Duygu Selcen ◽  
Andrew G. Engel ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Action Potential ◽  
Channel Blocker ◽  
Compound Muscle Action Potential ◽  
Response To Therapy ◽  
Congenital Myasthenic Syndrome ◽  
Blocker Therapy ◽  
Slow Channel ◽  
Study Laboratory ◽  
Therapy Treatment

ObjectiveTo find determinants of the occurrence of repetitive compound muscle action potential (R-CMAP) and to assess the efficacy of channel blocker therapy in slow-channel congenital myasthenic syndrome (SCCMS).MethodsNeurologic examination, EMG study, laboratory test, muscle biopsy, and next-generation and Sanger sequencing; literature review of reported patients with SCCMS, including EMG, kinetics of mutant acetylcholine receptors (AChRs), and response to therapy; and simulation of the decay phase of endplate potential (EPP) were performed.ResultsThree newly characterized and 57 reported patients with SCCMS with mutations of AChR subunits were included. In patients with R-CMAP, the length of channel opening bursts of mutant AChR was increased 8.68 ± 2.82 (mean ± SD)-fold compared to wild-type; in patients without R-CMAP, the length was increased 3.84 ± 0.65-fold (95% confidence interval 3.18–6.50, p = 0.000014). The EPP amplitude after refractory period of action potential in muscle fiber is above the threshold in patients with R-CMAP but below the threshold in patients without R-CMAP. In patients with good results from channel blocker therapy, treatment was initiated 11.60 ± 5.17 years after onset of symptoms; in patients with no to moderate benefit from channel blocker therapy, treatment was initiated 30.70 ± 12.72 years after onset (95% confidence interval −28.57 to −9.63, p = 0.00089).ConclusionsIn SCCMS, the R-CMAP occurrence is related to the extent of prolongation of the opening episodes of mutant AChR channel. Channel blocker treatment is more effective the sooner it is started after the onset of symptoms.Classification of evidenceThis study provides Class IV evidence that channel blocker therapy in patients with SCCMS improves symptoms.

Sign in / Sign up

Export Citation Format

Share Document